Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00712829 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents
A Phase 1 study, sponsored by Molecular Insight Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00712829 is a Phase 1 study that has completed, run by Molecular Insight Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT00712829, a Phase 1 study, has completed, sponsored by Molecular Insight Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a single blinded, randomized, cross-over design. Up to 12 patients will be randomly administered a single 10.0 mCi dose of 123I-MIP-1072 or 123I-MIP-1095 (study drugs). The second (alternate) study drug will be administered approximately 14 days after the first. A final follow-up visit will occur approximately 2 weeks after the injection of the alternate study drug.
Interventions
- DRUG 123-I-MIP-1072
- DRUG 123-I-MIP-1095
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00712829
The ClinicalTrials.gov registry entry for NCT00712829 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molecular Insight Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 123-I-MIP-1072 is the first listed.
NCT00712829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00712829 about?
NCT00712829 is a clinical study titled "Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents". This is a single blinded, randomized, cross-over design. Up to 12 patients will be randomly administered a single 10.0 mCi dose of 123I-MIP-1072 or 123I-MIP-1095 (study drugs). The second (alternate) study drug will be administered approximately 14 days after the first. A final follow-up visit will ...
What is the current status of trial NCT00712829?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2008-05. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00712829?
The interventions under investigation include: 123-I-MIP-1072 (DRUG), 123-I-MIP-1095 (DRUG).
Who is sponsoring clinical trial NCT00712829?
This trial is sponsored by Molecular Insight Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.